Israel's Hadasit Bio Receives $2 Million from China Investors

Hadasit Bio Holdings, a holding company for medical technology developed at Hadassah Medical Center in Jerusalem, announced a $2 million investment from unspecified Chinese investors. The investors will receive 25% of the company's shares and preferential treatment on China rights to any products. If additional investment is supplied, Hadasit will form a China development unit. At present, it has six portfolio companies. More details.... Stock Symbols: (TASE: HDST; OTCBB: HADSY) Share this with colleagues: // //